FMC stock is trading near US$10 after a steep multi year slide, yet the company still screens as undervalued on several checks. This raises questions about whether the share price reflects excessive pessimism or a reset to a more realistic level.

• FMC shareholders have seen the stock fall 87.0% over the past 3 years, which points to a heavy reset in market expectations for the business.
• Future cash generation and balance sheet resilience are likely to be the main swing factors for FMC's valuation, since they can support or limit how quickly the business can turn sentiment around.
• On Simply Wall St's broader checks, FMC looks cheap, with the stock passing 5 of 6 valuation tests. This suggests the current market price embeds cautious assumptions. 5/6 valuation score

The issue now is whether FMC's depressed share price is a value opportunity or a sign that the market expects prolonged pressure on the business.

Is FMC Still Cheap on Sales?

P/S is a useful yardstick for FMC because revenue is still the main anchor for how investors size up the business while earnings remain weak.

FMC is trading on a P/S multiple of about 0.4x, which is well below the Chemicals industry average of 1.2x and also below the broader peer group at roughly 1.4x. Simply Wall St’s fair P/S ratio for FMC is 1.6x, which is higher than both the industry average and the current market multiple.

This fair ratio reflects what investors might typically pay for a company with FMC’s profile, after factoring in its risks and current conditions. The large gap between the current 0.4x and the 1.6x fair ratio suggests the stock is pricing in a lot of caution around future revenue quality and recovery potential.

On this P/S measure, FMC stock appears undervalued compared with both its sector and the modelled fair multiple.

The FMC Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for FMC act as the bridge between the current valuation puzzle and the assumptions that would need to hold around FMC's future growth, margins and earnings for the stock to be worth significantly more or less than today's price, and they sit on the company’s Community page. Instead of stopping at a single ratio or model output, Narratives lay out the future that number assumes so you can watch how the real business lines up with it over time.

One of the top community narratives on FMC: 36% undervalued

"Ongoing cost transformation, including lower manufacturing costs for key products like Rynaxypyr and benefits from 2024 to 2025 restructuring, is expected to create durable COGS reductions and improved fixed cost absorption…"

Do you think there's more to the story for FMC? Head over to our Community to see what others are saying!

The Bottom Line

FMC screens as undervalued on market multiples, with a large gap between its current P/S and what investors typically pay for similar businesses. That discount only matters if FMC can stabilise revenue quality and show that margins and cash generation are on a firmer footing. For now, the key debate is whether the low multiple is an opportunity for patient investors or an accurate warning that the recovery in the underlying business could be slower or more challenging than hoped.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.